10-Q: Quantumzyme Corp. Faces Severe Financial Distress Amidst Mounting Losses and Going Concern Doubts

Quantumzyme Corp. reported a significant net loss and a substantial accumulated deficit for the nine months ended April 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Quantumzyme Corp. (formerly Reliant Services, Inc.) reported no revenues for the three or nine months ended April 30, 2025, or the comparable periods in 2024.
• The company incurred a net loss of $161,092 for the nine months ended April 30, 2025, an increase from $137,341 for the same period in 2024.
• Operating expenses increased to $145,921 for the nine months ended April 30, 2025, up from $126,398 in the prior year, primarily due to increased professional fees.
• Interest expense rose to $15,171 for the nine months ended April 30, 2025, compared to $10,943 in the prior year, driven by additional debt.
• The accumulated deficit reached $5,598,390 as of April 30, 2025, up from $5,437,298 as of July 31, 2024.
• Cash used in operating activities was $116,550 for the nine months ended April 30, 2025, an increase from $88,187 in the prior year.
• Total current assets were only $584 as of April 30, 2025, while total current liabilities stood at $403,125, resulting in a working capital deficit of $402,541.
• The company issued 4,185,000 shares of common stock for $41,850 cash and incurred $75,284 in new promissory notes during the nine months ended April 30, 2025.
• As of April 30, 2025, total notes payable amounted to $240,451, up from $167,666 as of July 31, 2024.
• The company's management concluded that its disclosure controls and procedures and internal control over financial reporting were not effective as of April 30, 2025, citing limited internal resources and lack of multiple levels of transaction review.

Sentiment

Score: 1

Explanation: The company is in severe financial distress with no revenue, increasing losses, a critical cash shortage, and significant doubt about its ability to continue as a going concern. Internal controls are deemed ineffective, and there are no clear paths to immediate improvement or funding.

Negatives

• The company reported zero revenue for the current and prior periods, indicating no operational income.
• Significant net losses continue to accumulate, reaching $161,092 for the nine months ended April 30, 2025.
• The accumulated deficit has grown to $5,598,390, highlighting a substantial historical loss position.
• The company has a severe working capital deficit of $402,541, with current assets of only $584 against current liabilities of $403,125.
• Cash used in operations increased, indicating a worsening burn rate from core activities.
• Total liabilities, particularly notes payable, have increased significantly, adding to financial strain.
• The company is entirely dependent on external funding and has no firm agreements for future financing, raising significant liquidity concerns.
• Management explicitly stated that disclosure controls and internal control over financial reporting were not effective, citing material weaknesses due to limited resources and lack of segregation of duties.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses, accumulated deficit, and negative cash flows from operations.
• Complete dependence on attracting and receiving funding from the sale of securities or outside sources (private investment, strategic partner) with no assurance of availability on acceptable terms or at all.
• Inability to obtain sufficient funding will restrict growth, reduce business operations, and may lead to suspension of operations, resulting in a loss for common stock purchasers.
• Any additional equity financing, if obtained, may involve substantial dilution to existing stockholders.
• Material weakness in financial reporting due to insufficient dedicated resources, experienced personnel, and lack of segregation of duties, increasing the risk of material misstatements not being prevented or detected.
• Absence of an audit committee or an independent audit committee financial expert, which management views as an important entity-level control, further exacerbating control deficiencies.
• The 1-to-100 reverse stock split approved by the Board of Directors on March 31, 2023, has not yet been approved by FINRA, creating uncertainty regarding its effective implementation.

Future Outlook

The company expects operating expenses to increase in future years due to costs associated with increased operating activity under its business model. It is entirely dependent on attracting and receiving funding from either the sale of securities or outside sources such as private investment or a strategic partner, with no assurance that needed funds will be available. The inability to obtain sufficient funding will restrict growth, reduce business operations, and may require the suspension of operations. Any additional equity financing may involve substantial dilution to existing stockholders.

Management Comments

• "We expect our operating expenses will increase in future years as a result of the costs associated with the increased operating activity under our business model."
• "We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner."
• "We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all."
• "The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations."
• "Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock."
• "If we are unable to obtain necessary financing, we will likely be required to curtail our development plans."
• "Any additional equity financing may involve substantial dilution to our then existing stockholders."
• Management concluded that their financial disclosure controls and procedures were not effective due to limited internal resources and lack of ability to have multiple levels of transaction review, but believes the financial statements are materially correct.

Industry Context

Quantumzyme Corp. operates in the Enzyme Catalyst biotransformation sector, a specialized area within biotechnology. The company's current financial state, characterized by zero revenue and significant losses, suggests it is in a very early stage of development or facing severe operational challenges. Without revenue, it is not participating meaningfully in industry trends or competing effectively. Its reliance on external funding for basic operations indicates it is far from commercialization or sustainable growth, contrasting sharply with established players or even early-stage biotech firms that typically demonstrate R&D progress or initial market traction.

Comparison to Industry Standards

• Quantumzyme Corp.'s complete lack of revenue stands in stark contrast to typical industry standards for even early-stage biotechnology companies, which often report grant income, collaboration revenues, or initial product sales.
• The company's substantial accumulated deficit of over $5.5 million and negative cash flow from operations are common for pre-revenue biotech startups, but the absence of any offsetting positive developments (e.g., significant R&D milestones, clinical trial progress, or major partnership announcements) makes its financial position particularly precarious.
• The company's cash balance of only $584 is critically low, far below the liquidity levels typically maintained by even small biotechnology firms to cover operational expenses or fund research, indicating an immediate and severe liquidity crisis.
• The explicit disclosure of 'not effective' internal controls and material weaknesses is a significant red flag, indicating a lack of robust financial governance and operational oversight, which is below the standard expected for publicly traded companies, regardless of size.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings.

Related Party Transactions

• Amounts due to related parties were $17,002 as of April 30, 2025, and $15,852 as of July 31, 2024. These amounts are non-interest bearing and due on demand.

Stakeholder Impact

• **Shareholders**: Face significant risk of substantial dilution from future capital raises and potential loss of investment if the company fails to secure funding and continues as a going concern. The ineffective internal controls also pose a risk to the reliability of financial information.
• **Creditors**: Face increased risk due to the company's severe liquidity issues, growing notes payable, and going concern doubt, which may impair the company's ability to repay its debts.
• **Employees**: While not explicitly mentioned, the company's precarious financial position and dependence on external funding suggest potential instability in employment and operations.
• **Customers/Suppliers**: The company's lack of revenue and operational instability suggest minimal current impact, but any future business relationships would be at high risk due to the going concern issues.

Next Steps

• Management intends to take practical, cost-effective steps to implement internal controls, including assessing current duties, assigning additional duties, potentially hiring additional personnel, and considering an audit committee and financial expert, upon obtaining sufficient capital and operations.

Key Dates

Recommendation

Keywords

Quantumzyme Corp, SEC 10-Q, Quarterly Report, Financial Statements, Going Concern, Net Loss, Accumulated Deficit, Working Capital Deficit, Promissory Notes, Internal Controls, Disclosure Controls, Material Weakness, Biotechnology, Enzyme Catalyst, Biotransformation, Corporate Governance, Stock Split, Preferred Stock, Liquidity, Capital Resources